tbuckley/cabot-search huggingface dataset:
Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer
Authors: Miho Kono, Takeo Fujii, Bora Lim, Meghan Sri Karuturi, Debasish Tripathy, Naoto T. Ueno
Journal: JAMA Oncology (2017)

The androgen receptor (AR) pathway is emerging as a potential therapeutic target in breast cancer. To date, AR-targeted drugs have been approved only for treatment of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investigation. Through review of preclinical studies, retrospective clinical studies, and clinical trials, we examined the biology of AR and AR-related pathways, the potential for AR-targeted therapies in breast cancer, and potential biomarkers for AR-targeted treatments.The rate of AR positivity in breast cancer is about 60% to 80%. Biologically, the AR pathway has cross-talk with several other key signaling pathways, including the PI3K/Akt/mTOR and MAPK pathways, and with other receptors, including estrogen receptor and human epidermal growth factor receptor-2. The value of AR positivity as a prognostic marker has not yet been defined. Androgen receptor-targeted therapies, including AR agonists, AR antagonists, and PI3K inhibitors, have shown promising results in clinical trials in patients with breast cancer, and combinations of AR-targeted therapies with other agents have been investigated for overcoming resistance to AR-targeted therapies. Biomarkers to stratify patients according to the likelihood of response to AR-targeted drugs are yet to be established. Potential biomarkers of response to AR inhibitors include AR phosphorylation and AR gene expression.Androgen receptor-targeted treatments for breast cancer are in development and have shown promising preliminary results. In-depth understanding of AR and AR-related signaling pathways would improve the treatment strategies for AR-positive breast cancer. Further preclinical and clinical studies of AR-targeted drugs alone and in combination with other drugs are justified and warranted to clarify the biology of AR and inform the development of AR-targeted therapies to improve survival outcome in patients with breast cancer.
CORONARY ARTERY FISTULA IN PULMONARY ATRESIA WITH INTACT VENTRICULAR SEPTUM PHYSIOLOGY: TO CLOSE OR NOT TO CLOSE?
Authors: Ahmed Kheiwa, Ian Harris, Anushree Agarwal, Vaikom Mahadevan, Aarthi Sabanayagam, Phillip Moore
Journal: Journal of the American College of Cardiology (2017)
RAPID VENTRICULAR PACING DURING TAVR IS ASSOCIATED WITH POOR SHORT- AND LONG-TERM OUTCOME
Authors: Paul Fefer, Scott Kohen, Andrada Bogdan, Victor Guetta, Elad Asher, Elad Maor, Dan Elian, Ehud Regev, Noam Fink, Amit Segev, Israel M. Barbash
Journal: Journal of the American College of Cardiology (2017)
A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN).
Authors: Yuanjue Sun, Baorui Liu, Ping Liu, Changping Wu, Rongsheng Zheng, Xiaohua Zhang, Zhixiang Zhuang, Yongchuan Deng, Leizhen Zheng, Qing Xu, Bin Jiang, Xuenong Ouyang, Jianfei Gao, Su Jiang, Wei Zheng, Benjamin Xiaoyi Li, Yongqian Shu, Yang Yao
Journal: Journal of Clinical Oncology (2012)

9017 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of many commonly used chemotherapeutic. This side effect of chemotherapy can be debilitating and effective treatment for CIPN remains elusive. Previous studies demonstrated that Acetyl-L-Carnitine (ALC) is effective in attenuating CIPN, controlled study is needed to substantiate ALC’s effect in treatment of CIPN. Methods: This study was designed to evaluate the efficacy and safety of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablet (oral administration) in the treatment of CIPN. It was a prospective, randomized, double-blinded, placebo-controlled and paralleled clinical study (registration No. 2007L03540). Of 239 subjects enrolled in the study (NCI grade 2 or above), 118 subjects received 3g/day ALC orally for 8 weeks and 121 received placebo. Primary endpoint was set as improvement of peripheral neuropathy at least 1 grade and assessment was made in week 4, 8 and 12 after enrollment. Results: In full analyses set (FAS) and per-proposal set (PPS), the peripheral sensory neuropathy was significantly ameliorated in ALC group with 50.5% and 51.6% patients meeting the primary endpoint at week 8 and 12 respectively while only 24.1% and 23.1% of patients in the placebo group at week 8 and 12 respectively (p&lt;0.001 in both sets). Secondary endpoint such as nerve electrophysiological test and Physical Condition Score (Karnofsky performance status, KPS) were also significantly improved in patients with ALC treatment (in FAS, P=0.0463 and P=0.022; in PPS, P=0.0076and P=0.0064, respectively). Cancer-related fatigue was significantly alleviated after ALC treatment in PPS (P=0.0135). Safety: 236 subjects were included in safety assessment and 41 patients experienced 62 adverse events during the course of study. There was no significant difference in AE/SAE incidence between the two groups (P=0.3903). Conclusions: Oral administration of ALC is effective in attenuating CIPN as well as in reducing cancer-related fatigue and improving physical conditions in cancer patients. The treatment of oral ALC is safe and well tolerated.
Amplification of <i>CRKL</i> in human cancer: A rare event associated with potential sensitivity to targeted therapy.
Authors: Kai Wang, Adrienne Johnson, Ignacio Garrido-Laguna, Juliann Chmielecki, Roman Yelensky, Doron Lipson, Julia Andrea Elvin, Jo-Anne Vergilio, Siraj Mahamed Ali, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross
Journal: Journal of Clinical Oncology (2015)

1526 Background: CRKL amplification (amp) has been linked to tumor progression and adverse prognosis in solid tumors. Recent evidence suggests that CRKL amp may mediate resistance to EGFR inhibitors and may be associated with exceptional tumor response to Src kinase inhibitors. Methods: Next generation sequencing based comprehensive genomic profiling (CGP) using hybridization capture of 236 cancer-related genes was applied to ≥ 50 ng of DNA extracted from 33,000 FFPE specimens and sequenced to high, uniform median coverage (> 600X) and assessed for base substitutions, INDELs, copy number alterations and rearrangements. Clinically relevant genomic alterations (CRGA) were defined as those for which anti-cancer drugs on the market or in registered clinical trials could be identified. Results: CRKL amps (> 6 copies) were identified in 274 (0.8%) patients of median age 62 years (range 19-92) with 137 females and 137 males. There were 18 distinct tumor types featuring CRKL amp as show in the table below. Co-existent CRGA associated with CRKL amp were FGFR1 (7%), RICTOR (6%), ERBB2 (6%), KIT (6%), EGFR (5%), PTEN (5%), NF1 (5%) and AKT2 (5%). In 3 (1%) cases CRKL amp was the only GA and in 41 (15%) CRKL amp was the only CRGA. Of 6 CRKL amp cases with EGFR substitutions, 5 (83%) were in NSCLC consistent with a potential resistance mechanism to anti-EGFR therapy. Case examples of unanticipated major responses of tumors with CRKL amp treated with targeted therapies will be presented. Conclusions: CRKL amp is widely distributed across diverse tumor types and frequently associated with other druggable CRGA. CRKL amp may be associated with EGFR TKI resistance in NSCLC. Tumors with CRKL amp targeted with Src kinase inhibitors may be responsible for examples of exceptional clinical responses of advanced cancers to this class of therapy. Selected Tumor Types # of CRKL amp # of tumors analyzed % of tumors with CRKL amp Testis + mediastinum germ cell tumors 6 63 9.5% Bladder 14 562 2.5% Ovary 28 1464 1.9% Lung 81 6068 1.3% Unknown primary carcinoma 33 2779 1.2% Melanoma 20 1880 1.1% Liver + bile duct + gallbladder 7 675 1.0% Soft tissue + bone 11 1088 1.0% Uterus 7 717 1.0% Pancreas 10 1215 0.8% Gastrointestinal tract 23 4622 0.5% Breast 16 3988 0.4%
Defective macrophage function in crohn's disease: role of alternatively activated macrophages in inflammation
Authors: C. Karaiskos, B. N. Hudspith, T. Elliott, N. B. Rayment, V. Avgousti, J. D. Sanderson
Journal: Gut (2011)

<h3>Introduction</h3> The aetiology of Crohn9s disease (CD) involves a genetically determined dysregulated immune response to commensal intestinal microflora. In CD, viable <i>E coli</i> are found within lamina propria macrophages (MΦs) and <i>E coli</i> intracellular survival is prolonged in CD-derived MΦs in vitro. Different MΦ subpopulations exist, M1 cells are inflammatory cells, M2a cells are involved in tissue repair and M2c are regulatory cells that limit inflammation. The role these different MΦs play in this abnormal handling of bacteria in CD is unclear. <h3>Methods</h3> The aim of this study was to examine in vitro M1 and M2 MΦ maturation in CD patients and healthy individuals and how these cells respond to challenge with CD-derived <i>E coli.</i> To do this we monitored MΦ morphology, surface markers and cytokine production and intracellular bacterial survival. Peripheral blood monocytes were isolated from CD patients and healthy controls and treated with cytokines to generate distinct MΦ subpopulations: IFNγ for M1, IL4/IL13 for M2a and IL10 for M2c. MΦ morphology was assessed by H&amp;E staining and surface marker expression of CD14, CD16 and CD33, chemokine receptor CCR2, scavenger receptor CD163, co stimulatory molecule CD40 and mannose receptor CD206 using flow cytometry. IL10 and TNFα production were measured by ELISA and intracellular <i>E coli</i> survival was measured using the gentamicin protection assay. <h3>Results</h3> In contrast to M1 MΦ9s, both CD-derived M2 populations failed to develop the characteristic MΦ dendrite morphology seen in control macrophages. Surface expression of CD40 in M2 CD-derived MΦs was 3.4-fold lower for M2a and 4.4-fold lower for M2c compared to controls after <i>E coli</i> challenge. CD163 was higher in M1 CD cells but reduced by 50% in M2 cells compared to healthy cells. After <i>E coli</i> challenge, TNFα production by M2 but not M1 MΦs was significantly lower in CD than in controls (M2a 38%, M2c 27% respectively less than controls) but there were no differences in IL10 production. Prolonged intracellular survival of <i>E coli</i> was demonstrated in CD M2 cells but effective killing occurred in all M1 CD MΦs and all control MΦs. <h3>Conclusion</h3> In CD, M2 (but not M1) MΦs display abnormal morphological maturation, lower TNFα levels after <i>E coli</i> challenge, prolonged intracellular bacterial survival and differences in surface marker expression. The results are consistent with an innate MΦ defect in CD relating particularly to a failure of the normal role of M2 MΦs to limit and control inflammation.
Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.
Authors: Neha Korde, Adriana Zingone, Mary Kwok, Elisabet E. Manasanch, Manisha Bhutani, Rene Costello, Mary Ann Yancey, Marcia Mulquin, Katherine R. Calvo, Irina Maric, Prashant Tembhare, Constance Yuan, Maryalice Stetler-Stevenson, Diane Carol Arthur, Peter L. Choyke, Karen A Kurdziel, Seth M. Steinberg, Mark Raffeld, Mark J. Roschewski, Ola Landgren
Journal: Journal of Clinical Oncology (2012)

e18568 Background: Carfilzomib (Cz) is an irreversible proteasome inhibitor with potent anti-MM effects and decreased peripheral neuropathy rates compared to bortezomib. In this two-stage phase II trial of 45 planned patients, we treat newly diagnosed MM patients with Cz, lenalidomide(Ln), and dexamethasone (Dx). Methods: Eight 28-day cycles of induction comprises of Cz IV 20/36 mg/m 2 on days 1, 2, 8, 9, 15, 16; Ln oral 25 mg days 1-21; and Dx IV/oral 20/10 mg on days 1, 2, 8, 9, 15, 16, 22, 23. Transplant eligible patients undergo stem cell collection after 4 cycles of CRd and continue with induction. After 8 cycles of induction, patients with SD or better receive 12 cycles of Ln maintenance 10 mg days 1-21. Primary endpoint is ≥ grade 3 neuropathy. Bone marrow samples are collected at baseline, C1D2 (single agent Cz exposed), CR/end of cycle 8 (cycles 1-8), and CR/end of cycle 21 (cycles 9-21). Patients are evaluated for clinical biomarkers and MRD studies (flow cytometry, PCR, and FDG PET-CT) at regular time points. Results: Approximate enrollment rate is 1-2 patients/month. Six patients meeting eligibility criteria have been enrolled (2 male, 4 female; median age 58; age 42-74). Thus far, 5/6 patients are evaluable for toxicity and response (1-5 cycles, 2-4 cycles, 1-2 cycles, and 1-1 cycle). No patients have reported ≥ grade 3 neuropathy. Non-hematologic toxicity (≥ grade3) includes: 1 - LFT elevation and 1 - anxiety. One patient had ≥ grade3 hematologic toxicity with lymphopenia. After median 3 cycles of CRd, 3 patients achieved VGPR, 1 patient achieved PR, and 1 remained at SD. Mean decline in serum markers (M-protein or FLCs) was 87% (60-100%) among responders. One patient had 98% decline in FLCs after 1 cycle and a decrease in abnormal plasma cell burden to ≤ 2% by flow cytometry after 3 cycles. Updated results on additional patients and molecular/MRD studies (flow cytometry, PCR, and FDG PET-CT) will be presented at meeting. Conclusions: Combination therapy with CRd is a tolerable and effective regimen against upfront MM, evoking rapid and deep disease control.
Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up.
Authors: Anna Dodero, Francesco Spina, Franco Narni, Francesca Patriarca, Sergio Cortelazzo, Fabio Benedetti, Fabio Ciceri, Donatella Baronciani, Rosanna Scime', Enrico Pogliani, Alessandro Rambaldi, Francesca Bonifazi, Attilio Olivieri, Benedetto Bruno, Corrado Tarella, Paolo Corradini
Journal: Blood (2009)
AN INVESTIGATION OF THE EVOLUTION OF IMPLANTABLE CARDIAC MONITORS: A COMPARISON OF REVEAL XTTM AND REVEAL LINQTM BASED ON ACCURACY MEASUREMENTS AND PATIENT OUTCOMES POST-DEVICE IMPLANT
Authors: Abhishek Sethi, Melissa Buescher, Ross Garberich, Elizabeth Hoffman, Jay Sengupta
Journal: Journal of the American College of Cardiology (2017)
Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons
Authors: Mythri Mudireddy, Sahrish Shah, Terra L. Lasho, Daniela Barraco, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2016)
Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival.
Authors: Craig S. Sauter, Craig H. Moskowitz, Juliet N. Barker, Ann A. Jakubowski, Esperanza B. Papadopoulos, Miguel A. Perales, James W. Young, Marcel van den Brink, Andrew D. Zelenetz, Hugo R. Castro-Malaspina
Journal: Blood (2007)
Whole Exome and Transcriptome Analyses in Pediatric T-Cell Acute Lymphoblastic Leukemia
Authors: Masafumi Seki, Kenichi Yoshida, Shiraishi Yuichi, Kenichi Chiba, Hiroko Tanaka, Motohiro Kato, Ryoji Hanada, Satoru Miyano, Yasuhide Hayashi, Seishi Ogawa, Junko Takita
Journal: Blood (2014)
Development of preclinical models of human BT474 and MDA-MB-361 breast cancer that endogenously overexpress HER2 and that respond to trastuzumab.
Authors: Giulio Francia, Cynthia Rodriguez, Ping Xu, Shan Man, William Cruz-Munoz, Guido Bocci, Robert S Kerbel
Journal: Journal of Clinical Oncology (2012)

e11061 Background: The anti-Her-2 antibody trastuzumab can be effectively combined with chemotherapy to treat Her-2 positive metastatic breast cancers. However, Her-2 positive breast cancers readily develop resistance to trastuzumab based therapies, and new models are needed to study such resistance, and to find new therapeutic options. Methods: We began the in vivo selection of human Her-2 positive breast cancer cell lines, BT474 and MDA-MB-361, in Severely Compromised Immunodeficient (SCID) mice. Tumor cells were implanted orthotopically into the mammary fat pad of SCID mice, and resulting tumors were serially passaged into new hosts over a 3 year period. Results: The resulting variants grow rapidly in SCID mice. Variants of both BT474 and MDA-MB-361 respond in vivo to trastuzumab monotherapy (20mg/kg twice weekly, i.p.) compared to controls (p&lt;0.05). After 2-6 months of trastuzumab monotherapy, all variants developed resistance to trastuzumab; such resistant variants were adapted to tissue culture. BT474 variants produced a spontaneous lymph node metastasis in SCID mice, 10 months after the surgical resection of the orthotopically implanted primary tumor; this metastatic variant was also adapted to tissue culture. BT474 variants were tagged with luciferase and then implanted intracranially into SCID mice; the progressive growth of the tumors cells in the mouse brain was thereafter monitored for 3 months by bioluminescence imaging, which provides ample opportunity to test new treatments for brain metastases. MDA-MB-361 variants growing orthotopically responded (i.e. p&lt;0.05 vs. controls) to the combination therapy of trastuzumab (20mg/kg twice weekly, i.p.) plus chemotherapy; chemotherapy consisted of a bolus of cyclophosphamide (CTX, 100mg/kg, i.p) followed by a maintenance metronomic CTX (20mg/kg/day, p.o.) regimen. Conclusions: We developed two preclinical models of human Her-2 positive breast cancer which may be used to study trastuzumab based therapies, Her-positive metastatic breast cancer, the growth of Her-2 positive breast cancer at a secondary site (i.e. the brain), as well as the evolution of tumor resistance to trastuzumab based therapies.
MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).
Authors: Jeffrey Matous, David Samuel DiCapua Siegel, Hien Kim Duong, Claudia Kasserra, Lars Sternas, Christian Jacques, Kenneth Klesczewski, Mohamed H. Zaki, Jatin J. Shah
Journal: Journal of Clinical Oncology (2013)

8585^ Background: POM + LoDEX has shown significant clinical activity in RRMM pts including those refractory to lenalidomide and bortezomib. Renal impairment is a common comorbidity for MM pts, occurring in &gt; 40%. POM is extensively metabolized with less than 5% renally eliminated as parent drug. Thus, renal function may not substantively affect parent drug exposure. Previous POM trials excluded pts with severe renal impairment. MM-008 is a phase 1, multicenter, open-label study designed to assess the PK and safety of POM + LoDEX in RRMM pts and normal or impaired renal function. Methods: RRMM pts (≥ 1 prior therapy [Tx]) with creatinine clearance (CrCl) ≥ 60 ml/min (cohort A) or severe renal impairment (CrCl &lt; 30 ml/min [cohort B]) not requiring dialysis were included. Cohort A received POM 4 mg and cohort B received POM 2 mg or 4 mg D1-21/28-day cycle following a standard 3 + 3 dose-escalation design. Both cohorts received DEX 40 mg (20 mg for pts aged &gt; 75 y) D1, 8, 15, and 22. Cohort C will assess pts with severe renal impairment (CrCl &lt; 30 ml/min) requiring dialysis (up to 14 pts planned). Pts were not permitted to enroll in more than 1 cohort. G-CSF was not permitted in cycle 1. Tx continued until progressive disease or unacceptable toxicity. Results: As of Feb 5, 2013, 11 pts have been treated (8 pts in cohort A; 3 pts in cohort B at 2 mg). Age ranged from 46-71 y (cohort A) and 57-64 (cohort B). 5 pts were aged &gt; 65 y in cohort A (aged 66, 69 [n = 3], and 71 y); none in cohort B. 7 pts in cohort A have received &gt; 1 cycle of Tx; 5 pts have received ≥ 3 cycles. One pt in cohort B has received &gt; 3 cycles. All 3 pts in cohort B have completed 1 full cycle of Tx with no dose-limiting toxicities reported. Dose escalation is planned. The most common grade 3/4 adverse events (AEs) in cohort A were neutropenia (n = 3) and pneumonia (n = 2). No grade 3/4 AEs have been observed for pts in cohort B to date. POM dose reduction due to AE occurred in 2 pts (both in cohort A), all pts remain on study. PK and updated AE data will be presented at the meeting. Conclusions: MM-008 is an ongoing trial evaluating PK and safety in pts with renal impairment. Early tolerability data are encouraging. Clinical trial information: NCT01575925.
ASSOCIATION OF ENDOTHELIAL DYSFUNCTION WITH BIOMARKERS OF INFLAMMATION, MYOCARDIAL FIBROSIS AND LEFT VENTRICLE STRAIN IN PATIENTS WITH HEART FAILURE
Authors: Evangelos Oikonomou, Efstathios Dimitropoulos, Gerasimos Siasos, Antigoni Miliou, Christine Chrysohoou, Konstantinos Mourouzis, Georgia Vogiatzi, Alexios Antonopoulos, Mpourouki Evgenia, Sotirios Tsalamandris, George-Angelo Papamikroulis, Charilila-Loukia Ververeli, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
LONG-TERM OUTCOME WITH ORAL ANTICOAGULANTS WITH OR WITHOUT DUAL ANTIPLATELET THERAPY AFTER AMI: THE FAST-MI 2010 REGISTRY
Authors: Tabassome Simon, Etienne Puymirat, Francois Schiele, Guillaume Cayla, Loic Belle, Gilles Lemesle, Bernard Jouve, Meyer Elbaz, Nicolas Danchin
Journal: Journal of the American College of Cardiology (2017)
Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort
Authors: Craig Speziali, Andrew Daly, Mohamed Abuhaleeqa, Janet Nitta, Yasser Abou Mourad, Matthew D. Seftel, Kristjan Paulson
Journal: Blood (2016)
The relationship between older cancer survivors’ reports of depression, anxiety and pain to health providers’ findings and mortality
Authors: P. H. Seo, R. Sloane, S. S. Ingram, D. Misra, E. C. Clipp, G. S. Montana, H. J. Cohen
Journal: Journal of Clinical Oncology (2006)

8597 Background: Older cancer survivors may experience psychological distress due to their cancer experience and aging health. This study aimed to compare primary care and specialty providers’ inquiries of pain, depression and anxiety to older cancer survivors’ questionnaire responses. Methods: 153 patients seen in oncology clinics at the Veterans Affairs Medical Center (Durham, NC) from November 1999 until April 2000 completed the Hospital Anxiety and Depression Scale and a pain thermometer questionnaire. Blinded chart review examined health provider inquiries of pain, anxiety and depression. Cox proportional hazards survival analyses were performed on subjective pain, anxiety and depression with comorbidities and Karnofsky performance status (KPS) added in controlled models. Results: Patients were on average aged 68, had 5.4 comorbidities, 87.4% KPS, and were 3.1 years from a cancer diagnosis. Health providers missed 17 of 94 patients with significant levels of self-reported pain (sensitivity 0.82). Although 28 (20.6%) and 33 (25.8%) patients screened positively for depression and anxiety respectively, providers asked 7 patients about anxiety (sensitivity 0.15) and 16 patients about depression (sensitivity 0.25). The overall three year mortality was 37.9%. Pain was not associated with mortality. Patients screening for depression [HR 2.03 (95% CI: 1.03, 4.01)] and anxiety [HR 2.02 (95% CI: 1.01, 4.04)] had lower 3 year survival. KPS and comorbidities diminished these effects. Conclusions: In older cancer survivors, anxiety and depression may have an association with mortality. To improve detection, oncology and primary care providers should routinely inquire about mood and aim to intervene with pharmacologic or supportive treatments. No significant financial relationships to disclose.
EXTENDED COURSE OF RECOVERY IN PATIENTS WITH PERIPARTUM CARDIOMYOPATHY ASSESSED BY LEFT VENTRICULAR WALL DISTENSIBILITY
Authors: Masataka Sugahara, Dennis McNamara, Lori Blauwet, Rami Alharethi, Paul Mather, Kalgi Modi, Richard Sheppard, Vinay Thohan, Gretchen Wells, John Gorcsan
Journal: Journal of the American College of Cardiology (2017)